Buckhead Capital Management LLC Trims Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Buckhead Capital Management LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 19,149 shares of the medical research company’s stock after selling 1,961 shares during the quarter. Buckhead Capital Management LLC’s holdings in Charles River Laboratories International were worth $3,535,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in CRL. Exchange Traded Concepts LLC increased its position in shares of Charles River Laboratories International by 26.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,049 shares of the medical research company’s stock worth $1,191,000 after purchasing an additional 1,264 shares during the last quarter. Creative Planning grew its stake in Charles River Laboratories International by 4.0% in the third quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock worth $920,000 after purchasing an additional 180 shares in the last quarter. Wolff Wiese Magana LLC bought a new stake in Charles River Laboratories International in the third quarter valued at about $32,000. Mitchell & Pahl Private Wealth LLC raised its stake in Charles River Laboratories International by 5.0% during the third quarter. Mitchell & Pahl Private Wealth LLC now owns 3,311 shares of the medical research company’s stock valued at $652,000 after buying an additional 157 shares in the last quarter. Finally, Cardinal Capital Management lifted its holdings in Charles River Laboratories International by 3.1% during the 3rd quarter. Cardinal Capital Management now owns 10,504 shares of the medical research company’s stock worth $2,069,000 after buying an additional 312 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CRL. Bank of America lowered their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Monday, February 3rd. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $200.79.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $153.20 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm has a market capitalization of $7.83 billion, a price-to-earnings ratio of 19.17, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. The business has a 50 day simple moving average of $177.23 and a 200 day simple moving average of $191.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).